Directory snapshot
Durham biotech startups by stage
Of 17 startups with a recorded funding stage, 4 are at grant, pre-seed, or seed. Reviewed jobs records currently show 11 open roles across 6 companies.
- tracked startups
- 35
- hiring now
- 6
- grant through seed
- 4
11 reviewed open roles
Which Durham biotech startups are hiring
All 35 biotech startups headquartered in Durham
AimMax Therapeutics
Biotech
Develops drugs for infection and inflammation, including antibiotics for drug-resistant gonorrhea.
Altis Biosystems
Biotech · Seed
Intestinal tissue models for drug development
Arbiom
Biotech · Growth
Fermentation company developing Torula yeast strains that transform agricultural and forestry by-products into protein and functional ingredients for food and pet-food applications.
Atsena Therapeutics
Biotech · Series C
Gene therapy for inherited retinal diseases
Cell Microsystems
Biotech · Grant
Develops proprietary tools for basic biology research
EpiCypher
Biotech
Sells chromatin-mapping assay kits, designer nucleosomes and genomic services for epigenetics research and drug discovery.
EydisBio Inc.
Biotech · Grant
Durham biotechnology company developing selective small-molecule TAK1 inhibitors for autoimmune, inflammatory, fibrotic, neurodegenerative, and infectious diseases.
ForagR Medicines
Biotech
Drug discovery company that screens small molecules in living cells to target disease proteins through their messenger RNAs.
Gateway Bio
Biotech
Therapeutic biologics
GeneCentric
Biotech · Series C
Precision-oncology diagnostics company applying gene-expression biology to liquid-biopsy sequencing through its ExpressCT fragmentomics platform and biomarker services.
Grid Therapeutics
Biotech
Durham clinical-stage biotech developing tumor-specific therapeutic antibodies isolated from single human B cells.
IMMvention Therapeutix
Biotech
Preclinical biotech developing oral small-molecule BACH1 inhibitors for sickle cell disease and other chronic conditions, with its systemic program licensed to Novo Nordisk.
Junipero Therapeutics
Biotech
Develops antisense oligonucleotides that steer a cell's own gene regulators to raise or lower expression of disease-causing genes.
Kriya Therapeutics
Biotech · Growth
Gene therapy company developing AAV-based therapies for highly prevalent chronic diseases, including geographic atrophy, thyroid eye disease, and type 1 diabetes. Bicoastal since founding, with gene-therapy manufacturing and process development anchored in RTP and a Palo Alto office. Raised $320M Series D in September 2025, one of the largest NC life-sciences rounds of the year.
LadeRx
Biotech
Develops a manganese-based MRI contrast agent for quantitative myocardial perfusion imaging.
MAA Laboratories
Biotech
Triangle specialty pharmaceutical company developing nanoparticle drug products through the NanoCont continuous-manufacturing platform; pipeline reformulates approved small molecules via the 505(b)(2) pathway.
Metabolon
Biotech · Growth
Metabolomics platform and services company providing biochemical profiling for pharmaceutical, biotech, agriculture, and consumer research.
NabGen, Inc.
Biotech
Develops an antibody suppressant technology that inhibits anti-drug and autoimmune antibodies, including pre-existing immunity that blocks AAV gene therapy.
Novo Heal, Inc.
Biotech
Develops anti-scarring regenerative therapies for vocal fold injury.
Parion Sciences
Biotech
Develops therapies for defects of the innate mucosal defense system in respiratory disease.
Pelthos Therapeutics
Biotech · Growth
NYSE American-listed commercial-stage pharmaceutical company marketing ZELSUVMI for molluscum contagiosum.
Piximune, Inc.
Biotech
Develops antibody-based treatments for inherited retinal diseases and late-stage age-related macular degeneration.
Precision BioSciences
Biotech · Growth
Genome editing with ARCUS nuclease technology
Priovant Therapeutics
Biotech
Develops therapies for autoimmune diseases, including brepocitinib. NCBiotech reported its Durham operating base and the earlier FDA approval of Lisraya for adult dermatomyositis.
Ramona Optics
Biotech · Series A
Builds the Multi-Camera Array Microscope, a parallel imaging platform using micro-camera arrays, structured lighting and machine learning to capture cellular-level detail across hundreds of square centimeters at once.
Ribometrix
Biotech · Series A
Small molecule drug discovery platform targeting RNA structures
Roke Biotechnologies
Biotech
Develops engineered E. coli strains and two-stage processes that lower the cost of making proteins such as enzymes, therapeutic proteins, and agricultural peptides.
SelSym Biotech
Biotech
Develops SymClot, a synthetic platelet-mimetic hydrogel for controlling hemorrhage after trauma and surgery.
Sennos
Biotech · Growth
Durham-based industrial AI company building sensing, analytics, and automation for the fermentation and fluidics industries.
SiNON Nano Sciences
Biotech · Grant
Increases the ability of drugs to cross the Blood Brain Barrier
Tellus Therapeutics
Biotech · Series A
Develops treatments for newborns in the neonatal intensive care unit. Its lead candidate, TT-20, targets white matter brain injury in preterm infants and grew out of Duke research on compounds in breast milk that restore myelination.
Ten63 Therapeutics
Biotech · Series B
AI platform for cancer drug discovery
Tune Therapeutics
Biotech · Series B
Epigenome editing therapeutics for chronic diseases
Ummino
Biotech
Produces Hummino, a precision-fermented prebiotic modeled on human milk oligosaccharides, for adult gut health.
Veil Therapeutics
Biotech
Develops polymer-conjugated biologics built to avoid immune detection, led by a uricase candidate for chronic gout.
Exited biotech companies headquartered in Durham
These companies have been acquired, taken private, or taken public, so each is listed with its exit and left out of the startup count above.
Cereius
Biotech
Duke spinout that developed targeted radiodiagnostics and radiotherapeutics for cancer that has spread to the brain.
Acquired by Solve Therapeutics, 2023, terms not disclosedOpus Genetics
Biotech
Clinical-stage gene therapy company developing treatments for inherited retinal diseases, traded on Nasdaq as IRD.
Acquired by Ocuphire Pharma, 2024, terms not disclosedBrowsing is free. Opening a company shows the basics; founders, funding, and signals are in the full profile behind a free account. Open roles across Triangle companies are tracked on the jobs page. Numbers refresh from the database.